amgen glp-1 drug π The next trillion-dollar war has begun Drugmakers including Eli Lilly, Novo Nordisk, Pfizer, Amgen, AstraZeneca and others are racing beyond today's drugs. New pills, monthly injections and next-generation obesity How GLP-1 medications are transforming
Description
Our guest is Dave Ricks, the CEO of Eli Lilly, the largest pharmaceutical company in the world

However, safety concerns have persisted for years regarding the pancreatic effects of GLP-1 RAs

2017Glucagon-like peptide 1 receptor activation augments cardiac output and improves cardiac efficiency in obese swine after myocardial infarction

A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-fl-naphthylamidE

Additionally, these medications have been shown to modestly reduce blood pressure and improve lipid profiles, further supporting cardiovascular health

2021: More than 10,000 semaglutide-related adverse events are reported to the FDA Adverse Reporting System (FAERS)
